Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
FVC Change from Baseline over 24 Weeks: ITT Population | ITT Population- SoC Subgroup Figure…